ScreenerHero

HUMA Humacyte, Inc.

NAS · US · Healthcare · Biotechnology · humacyte.com
0.4723USD-1.19%Mkt Cap: 131.20M $P/E: —

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of ana…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap131.20M USD
Enterprise Value119.76M USD
Revenue (TTM)2.12M USD
Gross Profit-7.66M USD
Net Income (TTM)-40.83M USD
Revenue/Share0.01 USD
Last Price0.4723 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees184
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.93
PEG—
EV/EBITDA-1.16
EV/Revenue56.47
P/S62.61
P/B4.23
EPS (TTM)-0.49
EPS (Forward)-0.25
52W Range
0.46001% of range2.550
52W High2.550 USD
52W Low0.4600 USD
Profitability
Gross Margin-376.05%
Oper. Margin-6649.26%
EBITDA Margin0.00%
Profit Margin-2003.58%
ROE-1313.38%
ROA-35.09%
Growth
Revenue Growth34.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-105.04M USD
CapEx (TTM)884.00K USD
FCF Margin-2753.10%
FCF Yield-44.51%
Net Debt-13.02M USD
Net Debt/EBITDA0.13
Balance Sheet
Debt/Equity20.86
Current Ratio6.21
Quick Ratio5.37
Book Value/Sh0.11 USD
Cash/Share0.29 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)1.850 USD
Upside (mean)+291.7%
Target Range1.000 USD – 4.000 USD
1.000+291.7% to mean4.000
# Analysts5
Ownership
Shares Out.277.80M
Float250.79M
Insiders5.66%
Institutions26.87%
Short Interest
Short Ratio4.7d
Short % Float11.52%
Short % Out.11.45%
Shares Short31.81M
Short (prev mo.)31.94M
Technical
SMA 500.6157 (-23.3%)
SMA 2000.8699 (-45.7%)
Beta2.44
S&P 52W Chg16.45%
Avg Vol (30d)5.45M
Avg Vol (10d)4.15M
Technical Indicators
RSI (14)32.5
MACD-0.0387
MACD Signal-0.0340
MACD Hist.-0.0047
BB Upper0.6214 USD
BB Middle0.5472 USD
BB Lower0.4730 USD
BB Width27.10%
ATR (14)0.0385 USD
Vol Ratio (20d)1.01x